The risk or severity of adverse effects can be increased when Osanetant is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Huperzine A. The risk or severity of adverse effects can be increased when Desloratadine is combined with Tetrabenazine. The risk or severity of adverse effects can be increased when Pirenzepine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Quinidine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Topiramate. The risk or severity of adverse effects can be increased when Morphine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desloratadine. The risk or severity of adverse effects can be increased when Dicyclomine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Pentobarbital is combined with Desloratadine. Desloratadine may increase the anticholinergic activities of Glycopyrronium. The risk or severity of adverse effects can be increased when Benzatropine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Felbamate is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Methylscopolamine bromide. The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Physostigmine. The risk or severity of adverse effects can be increased when Methocarbamol is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Iloperidone. Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. The serum concentration of Edoxaban can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Ziconotide. The risk or severity of adverse effects can be increased when Brotizolam is combined with Desloratadine. The risk or severity of adverse effects can be increased when Isoflurane is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Vigabatrin. The risk or severity of adverse effects can be increased when Methohexital is combined with Desloratadine. The risk or severity of adverse effects can be increased when Barbital is combined with Desloratadine. The risk or severity of adverse effects can be increased when Protriptyline is combined with Desloratadine. The risk or severity of adverse effects can be increased when Clidinium is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Butylscopolamine. The risk or severity of adverse effects can be increased when Ethopropazine is combined with Desloratadine. The serum concentration of Cilostazol can be increased when it is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Galantamine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Pomalidomide. The risk or severity of adverse effects can be increased when Clozapine is combined with Desloratadine. The serum concentration of Ranolazine can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Clonazepam. The risk or severity of adverse effects can be increased when Lofentanil is combined with Desloratadine. The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desloratadine. The risk or severity of adverse effects can be increased when Biperiden is combined with Desloratadine. The serum concentration of Bendroflumethiazide can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Clonidine is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Methanesulfonyl Fluoride. The risk or severity of adverse effects can be increased when Oxymorphone is combined with Desloratadine. The risk or severity of adverse effects can be increased when Lamotrigine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Desloratadine. The risk or severity of adverse effects can be increased when Canertinib is combined with Desloratadine. The risk or severity of adverse effects can be increased when DPDPE is combined with Desloratadine. The serum concentration of Metoprolol can be increased when it is combined with Desloratadine. Ritobegron may decrease the sedative activities of Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Escitalopram. The risk or severity of adverse effects can be increased when Dapiprazole is combined with Desloratadine. The risk or severity of adverse effects can be increased when Enflurane is combined with Desloratadine. The risk or severity of adverse effects can be increased when Tiapride is combined with Desloratadine. The risk or severity of adverse effects can be increased when Butamben is combined with Desloratadine. The risk or severity of adverse effects can be increased when Buspirone is combined with Desloratadine. The serum concentration of Ledipasvir can be increased when it is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with 1,10-Phenanthroline. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Tacrine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Desvenlafaxine. The serum concentration of Brentuximab vedotin can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Pancuronium. The risk or severity of adverse effects can be increased when Indiplon is combined with Desloratadine. Mephedrone may decrease the sedative activities of Desloratadine. Diethylpropion may decrease the sedative activities of Desloratadine. The risk or severity of adverse effects can be increased when Gabapentin is combined with Desloratadine. The risk or severity of adverse effects can be increased when Aceprometazine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Desloratadine. 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Desloratadine. The risk or severity of adverse effects can be increased when Adipiplon is combined with Desloratadine. The risk or severity of adverse effects can be increased when Amobarbital is combined with Desloratadine. The serum concentration of Everolimus can be increased when it is combined with Desloratadine. Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Desloratadine. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine. The risk or severity of adverse effects can be increased when Rufinamide is combined with Desloratadine. The therapeutic efficacy of Betahistine can be decreased when used in combination with Desloratadine. The risk or severity of adverse effects can be increased when Etomidate is combined with Desloratadine. The risk or severity of adverse effects can be increased when Dyclonine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Clemastine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Dexetimide is combined with Desloratadine. The risk or severity of adverse effects can be increased when Tramadol is combined with Desloratadine. The risk or severity of adverse effects can be increased when Thiopental is combined with Desloratadine. The risk or severity of adverse effects can be increased when Agomelatine is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Malathion. The risk or severity of adverse effects can be increased when Oxprenolol is combined with Desloratadine. Desloratadine may increase the constipating activities of Eluxadoline. The risk or severity of adverse effects can be increased when Alfaxalone is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Cyclizine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Vecuronium. The risk or severity of adverse effects can be increased when Pramocaine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Etorphine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Ethotoin is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Oxybutynin. The risk or severity of adverse effects can be increased when Allopregnanolone is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Dantrolene. The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Indalpine. The risk or severity of adverse effects can be increased when Amperozide is combined with Desloratadine. The risk or severity of adverse effects can be increased when Zonisamide is combined with Desloratadine. Desloratadine may increase the sedative activities of Metyrosine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Doxepin. MMDA may decrease the sedative activities of Desloratadine. Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. The risk or severity of adverse effects can be increased when Ethosuximide is combined with Desloratadine. The risk or severity of adverse effects can be increased when Haloperidol is combined with Desloratadine. Dextroamphetamine may decrease the sedative activities of Desloratadine. The risk or severity of adverse effects can be increased when Fencamfamine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Carisoprodol is combined with Desloratadine. The risk or severity of adverse effects can be increased when Butorphanol is combined with Desloratadine. The risk or severity of adverse effects can be increased when Butethal is combined with Desloratadine. The risk or severity of adverse effects can be increased when Eltanolone is combined with Desloratadine. The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desloratadine. The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desloratadine. The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Guanfacine. Droperidol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Homatropine. The serum concentration of Rifaximin can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Nitrazepam is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Desipramine. The serum concentration of Cyclopenthiazide can be increased when it is combined with Desloratadine. The risk or severity of adverse effects can be increased when Perazine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Promethazine. The risk or severity of adverse effects can be increased when Estazolam is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Rivastigmine. The risk or severity of adverse effects can be increased when Quetiapine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desloratadine. The therapeutic efficacy of Desloratadine can be decreased when used in combination with Edrophonium. The risk or severity of adverse effects can be increased when Dextromoramide is combined with Desloratadine. The serum concentration of Quinethazone can be increased when it is combined with Desloratadine.